CN103432011A - N-酰基氨基酸作为人皮肤真皮的衰老复制性成纤维细胞的遗传特性的调节活性剂的用途 - Google Patents
N-酰基氨基酸作为人皮肤真皮的衰老复制性成纤维细胞的遗传特性的调节活性剂的用途 Download PDFInfo
- Publication number
- CN103432011A CN103432011A CN2013103468131A CN201310346813A CN103432011A CN 103432011 A CN103432011 A CN 103432011A CN 2013103468131 A CN2013103468131 A CN 2013103468131A CN 201310346813 A CN201310346813 A CN 201310346813A CN 103432011 A CN103432011 A CN 103432011A
- Authority
- CN
- China
- Prior art keywords
- people
- acid
- palmityl
- aging
- fibroblasts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002950 fibroblast Anatomy 0.000 title abstract description 33
- 210000004207 dermis Anatomy 0.000 title abstract description 10
- 230000001105 regulatory effect Effects 0.000 title abstract description 6
- 230000003362 replicative effect Effects 0.000 title abstract description 4
- 239000013543 active substance Substances 0.000 title abstract 2
- 230000002068 genetic effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 230000037303 wrinkles Effects 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 15
- 239000004471 Glycine Substances 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 11
- 229960000310 isoleucine Drugs 0.000 claims description 10
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 10
- NDHKAEBPGBKCIO-SFHVURJKSA-N (2s)-2-(hexadecylamino)propanoic acid Chemical compound CCCCCCCCCCCCCCCCN[C@@H](C)C(O)=O NDHKAEBPGBKCIO-SFHVURJKSA-N 0.000 claims description 9
- 230000009758 senescence Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000032683 aging Effects 0.000 abstract description 42
- 229940024606 amino acid Drugs 0.000 abstract description 6
- 235000001014 amino acid Nutrition 0.000 abstract description 6
- 239000002537 cosmetic Substances 0.000 abstract description 5
- 230000003712 anti-aging effect Effects 0.000 abstract description 2
- 210000004927 skin cell Anatomy 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- NRBFOSKZAWRBJI-KRWDZBQOSA-N N-Palmitoyl alanine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](C)C(O)=O NRBFOSKZAWRBJI-KRWDZBQOSA-N 0.000 abstract 1
- NGYZAEAXQQNUBZ-FPOVZHCZSA-N N-Palmitoyl isoleucine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)[C@@H](C)CC NGYZAEAXQQNUBZ-FPOVZHCZSA-N 0.000 abstract 1
- KVTFEOAKFFQCCX-UHFFFAOYSA-N N-hexadecanoylglycine Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(O)=O KVTFEOAKFFQCCX-UHFFFAOYSA-N 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 25
- 239000003921 oil Substances 0.000 description 25
- 235000019198 oils Nutrition 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 20
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 19
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 19
- 210000002744 extracellular matrix Anatomy 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 19
- 230000003213 activating effect Effects 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- -1 alkali metal salt Chemical class 0.000 description 13
- 239000000284 extract Substances 0.000 description 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 11
- 235000004279 alanine Nutrition 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 229920001577 copolymer Polymers 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 206010040954 Skin wrinkling Diseases 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 229920001296 polysiloxane Polymers 0.000 description 9
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 8
- 102000007000 Tenascin Human genes 0.000 description 8
- 108010008125 Tenascin Proteins 0.000 description 8
- 230000003796 beauty Effects 0.000 description 8
- 102000005162 pleiotrophin Human genes 0.000 description 8
- 239000001993 wax Substances 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 150000003839 salts Chemical group 0.000 description 7
- 210000000582 semen Anatomy 0.000 description 7
- 102100036411 Dermatopontin Human genes 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 229920001519 homopolymer Polymers 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000009759 skin aging Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241001597008 Nomeidae Species 0.000 description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 5
- 230000003328 fibroblastic effect Effects 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 102000016362 Catenins Human genes 0.000 description 4
- 108010067316 Catenins Proteins 0.000 description 4
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 description 4
- 108010001394 Disaccharidases Proteins 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 4
- 101150101510 Hsp90aa1 gene Proteins 0.000 description 4
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 4
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 4
- 102000008730 Nestin Human genes 0.000 description 4
- 108010088225 Nestin Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000005055 nestin Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
- 101000601047 Homo sapiens Nidogen-1 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 102100037369 Nidogen-1 Human genes 0.000 description 3
- 229920002367 Polyisobutene Polymers 0.000 description 3
- 101000959867 Solanum tuberosum Aspartic protease inhibitor 9 Proteins 0.000 description 3
- 102100035071 Vimentin Human genes 0.000 description 3
- 108010065472 Vimentin Proteins 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 210000003953 foreskin Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000005048 vimentin Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 101710088341 Dermatopontin Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 2
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 240000003834 Triticum spelta Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 125000005250 alkyl acrylate group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000007799 cork Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000012182 japan wax Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 1
- LNZXVHVGGIYANQ-FQEVSTJZSA-N (2s)-1-hexadecylpyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCCN1CCC[C@H]1C(O)=O LNZXVHVGGIYANQ-FQEVSTJZSA-N 0.000 description 1
- ZEGPKOUXKGKNMP-IBGZPJMESA-N (2s)-2-(hexadecylamino)pentanedioic acid Chemical compound CCCCCCCCCCCCCCCCN[C@H](C(O)=O)CCC(O)=O ZEGPKOUXKGKNMP-IBGZPJMESA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 1
- LFJJOPDNPVFCNZ-UHFFFAOYSA-N 2-[hexadecanoyl(methyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N(C)CC(O)=O LFJJOPDNPVFCNZ-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
- 241000157280 Aesculus hippocastanum Species 0.000 description 1
- 235000006667 Aleurites moluccana Nutrition 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- 240000005589 Calophyllum inophyllum Species 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000227647 Fucus vesiculosus Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- OXPCWUWUWIWSGI-MSUUIHNZSA-N Lauryl oleate Chemical compound CCCCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC OXPCWUWUWIWSGI-MSUUIHNZSA-N 0.000 description 1
- 240000007225 Limnophila aromatica Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FDSLJAYOPNMZIY-UXHICEINSA-N N-Hexadecyl-L-hydroxyproline Chemical compound CCCCCCCCCCCCCCCCN1C[C@H](O)C[C@H]1C(O)=O FDSLJAYOPNMZIY-UXHICEINSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 241000651950 Phyllodium Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000605385 Ruscus Species 0.000 description 1
- 235000003500 Ruscus aculeatus Nutrition 0.000 description 1
- 102100027160 RuvB-like 1 Human genes 0.000 description 1
- 108050002982 RuvB-like helicase 1 Proteins 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 235000005794 Salvia japonica Nutrition 0.000 description 1
- 244000295490 Salvia japonica Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 241000221095 Simmondsia Species 0.000 description 1
- 241000220263 Sisymbrium Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 102100039662 Xaa-Pro dipeptidase Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229920006322 acrylamide copolymer Polymers 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000012754 barrier agent Substances 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 244000192479 candlenut Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical compound OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- QAKXLTNAJLFSQC-UHFFFAOYSA-N hexadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC QAKXLTNAJLFSQC-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 229960001983 magnesium aspartate Drugs 0.000 description 1
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- LAQFLZHBVPULPL-UHFFFAOYSA-N methyl(phenyl)silicon Chemical compound C[Si]C1=CC=CC=C1 LAQFLZHBVPULPL-UHFFFAOYSA-N 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012170 montan wax Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000008164 mustard oil Substances 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012168 ouricury wax Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920013639 polyalphaolefin Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000010491 poppyseed oil Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229940068988 potassium aspartate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108010066823 proline dipeptidase Proteins 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- DPBVJRXPSXTHOL-UHFFFAOYSA-N propyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCC DPBVJRXPSXTHOL-UHFFFAOYSA-N 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- LUPNKHXLFSSUGS-UHFFFAOYSA-M sodium;2,2-dichloroacetate Chemical compound [Na+].[O-]C(=O)C(Cl)Cl LUPNKHXLFSSUGS-UHFFFAOYSA-M 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- RKFCDGOVCBYSEW-AUUKWEANSA-N tmeg Chemical compound COC=1C(OC)=CC(C(OC(C=2OC)=C34)=O)=C3C=1OC(=O)C4=CC=2O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RKFCDGOVCBYSEW-AUUKWEANSA-N 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及N-酰基氨基酸作为人皮肤真皮的衰老复制性成纤维细胞的遗传特性的调节活性剂的用途、包含其的抗老化美容用组合物以及意欲延缓皱纹出现和/或减缓人体皮肤细胞老化的治疗方法的实施,其中N-酰基氨基酸选自N-棕榈酰基丙氨酸、N-棕榈酰基甘氨酸和N-棕榈酰基异亮氨酸。
Description
本申请是申请号为200980133503.3的中国专利申请的分案申请。
发明领域
本发明涉及美容用和药用活性成分领域,并且还涉及包含其的局部用组合物。
背景技术
在发达国家中对生命期望的增加已经持续地伴随着无法抑制的对“恢复青春”的渴望,这在过去30年左右变得更加明显并且这导致了尝试延缓(如果看不见消失)皮肤老化迹象如特别是皱纹的出现。这种行为变化已经伴随着致力于皮肤的科学研究的发展,并且在约10年中也伴随着“抗老化”美容用产品市场的快速增长。
本发明属于研究如下新分子或组合物的内容:所述新分子或组合物当应用于皮肤时通过其自身活性产生这种“抗老化”作用。
皮肤老化机制可以以以下方式来解释:
皮肤由两种主要的组织组成:真皮和表皮(其更加浅表),位于两者之间的是交界区——真皮表皮界。
-真皮是致密和纤维弹性的结缔组织,其产生和任何重塑基本上由成纤维细胞进行,其由细胞外基质(ECM)组成,细胞外基质由负责皮肤美观性质的纤维性(胶原和弹性)分子组成,并且其还由基质组成。胶原占真皮干重的98%。基质由如下组成:
-填充细胞和纤维之间空间的大分子;
-结构糖蛋白,其允许细胞与ECM连接并且基本位于真皮表皮界以 下;
-蛋白聚糖,包括糖胺聚糖(GAGs),它是与蛋白质结合的形式(共价键合),或者双糖链蛋白聚糖。
-表皮基本上由角质形成细胞组成。这些细胞在基层增殖,然后逐渐分化形成表皮的各层,同时从底部迁移至表面,在表面处脱落。
-真皮表皮界(DEJ)是位于表皮的基底角质形成细胞和真皮之间的交界区。其特征是存在基膜,在基膜中ECM形成薄的和固体的网格。其由五种主要组分组成,即IV型胶原、层粘连蛋白、硫酸乙酰肝素、巢蛋白(或触觉蛋白)和纤连蛋白。
ECM和DEJ的完整性以及表皮分化特别取决于负责众多ECM组分的降解的酶MMP(基质金属蛋白酶)的存在。
许多外源性和内源性因素(包括氧化应激)造成强调老化过程中的炎性过程,例如白细胞介素-6(IL-6)的产生(Ramasamy等人,2005;Papanicolaou等人,2006;Vaeto等人,2007)。在皮肤老化期间,上文所列的一种或其它或数种DEJ分子被自由基改变。
目前有许多“抗老化”或“抗皱”活性成分。其中一些能够调节正常人成纤维细胞的表型和/或性质。例如,许多美容用活性成分刺激通过成纤维细胞进行的胶原生成。因此,在美容应用中所用的LAAs中,有一些具有抗老化生物学性质,例如二棕榈酰基羟脯氨酸(SepiliftTM DPHP)。
作为US2006/024375公开的美国专利申请公开:向粉底化妆品中掺入N-棕榈酰基脯氨酸、N-棕榈酰基谷氨酸和N-棕榈酰基肌氨酸的混合物产生了皮肤保护作用和抗老化作用,这些作用由于其对皮肤的抗炎性质和作为P物质拮抗剂起作用因而是特别较高的。
作为US2007/0048396公开的美国专利申请公开了N-椰油酰基氨基酸、天冬氨酸镁和天冬氨酸钾的混合物对皮肤的抗炎性质。
另一方面,几乎没有“抗老化”活性成分已知能够引起炎性组分减少、特别是IL-6表达水平降低。具体而言,虽然某些抗氧化剂能够减少与老化相关的IL-6产生(Walston等人,2006;Omoigui,2007),但是这类作用不一定与调节ECM产生或对其进行保护的能力相关。相反,一些活性成分如 视黄醇被描述为引起发炎(Kim等人,2003)。另外,一些抗炎药用分子导致ECM组分如胶原纤维的产生减少(Miltyk等人,1996)。因此,在一方面活性成分的抗炎性质和另一方面其抗老化效力之间没有明显的相关性。
为了使皮肤老化作用可见和然后改正它们,已经描述了各种实验模型。因此,在单层成纤维细胞培养的情况下,各种刺激在体外可导致老化加速。
-例如,为了模拟光老化和/或氧化应激,能够使这些细胞接受紫外辐射的照射(Ma等人,2001;Kawanishi和Oikawa,2004;Chen等人,2007)。
-通过培养和研究来自老年供体的细胞也可以在体外复制老化[Albini等人,(1988);Miyoshi等人,(2006)]。
-最后,按照Hayflick’s模型,通过以使得它们进行大量群体倍增的方式培养成纤维细胞可以复制衰老(Bradley、Hayflick和Schimke,1976;Albini等人,1988)。该过程通常被称为“复制衰老”。
因此,这些原代培养物的实验性老化模型可用于评价美容用活性成分改正皮肤老化引起的缺陷和/或表型或生物学功能扩大的能力。因此,很多活性成分限制了UV-照射的成纤维细胞中的MMP蛋白生成。其它活性成分能够部分地恢复晚传代成纤维细胞中的基因或蛋白质的活性。
但是,一些研究在细胞系上进行,而不是在原代培养物上进行。
现在,以它们以事实上不受限的方式使群体翻倍的能力表征细胞系。该过程相应于无限增殖化(Goldstein,1990;Rhim,1991;Macieira-Coelho,2000)。因此,通常认为:与对等的原代培养物相比,细胞系显示出某些差异。因此,它们不反映生理现实,特别是对于老化而言。而且,在人成纤维细胞的原代培养物的情况下,大多数研究采用来源于包皮的细胞进行。但是,与来源于成人真皮的人成纤维细胞相比,这些包皮表现出特定的性质(Jelaska和Korn,1998;Khorramizadeh等人,1999;Saguet等人,2006)。具体而言,通常认为这些成纤维细胞表现出增加的增殖能力。它们对氧化应激的敏感性也表现出不同(Saguet等人,2006)。因此,使用与最终将被抗老化活性成分所靶向的那些细胞相同来源的细胞、即成人真皮的细胞更具有相关性。现在,据我们所知,没有N-酰基氨基酸已经被描述为能够以减少炎症并同时促进ECM生成或保护的方式调节来源于成人真皮的复制衰 老性成纤维细胞(replicative senescent fibroblasts)的遗传特性。
发明内容
根据第一方面,本发明的主题是作为调节人皮肤真皮的复制衰老性成纤维细胞的遗传特性的活性剂的N-酰基氨基酸,所述N-酰基氨基酸选自N-棕榈酰基丙氨酸、N-棕榈酰基甘氨酸、N-棕榈酰基异亮氨酸和N-椰油酰基丙氨酸。
根据第二方面,本发明的主题还有N-酰基氨基酸在实施意欲延缓皱纹出现和/或减缓人体皮肤细胞老化的治疗方法中的用途,所述N-酰基氨基酸选自N-棕榈酰基丙氨酸、N-棕榈酰基甘氨酸、N-棕榈酰基异亮氨酸和N-椰油酰基丙氨酸。
表述“调节人皮肤真皮的复制衰老性成纤维细胞的遗传特性”更特别地指如上文定义的N-酰基氨基酸具有下述性质中的一种或其它、数种或全部:
-其引起编码促炎细胞因子IL-6的基因的表达水平降低;
-其引起编码MMP-1的基因的表达水平降低,MMP-1是参与细胞外基质降解的金属蛋白酶;
-其引起编码促炎蛋白、serpin2B或PAI-2(纤维蛋白溶酶原激活物抑制剂-2)的基因的表达水平降低(Kessler-Becker等人,2004);
-其引起编码真皮组分皮肤桥蛋白(dermatopontin)(DPT)的基因的表达水平增加,皮肤桥蛋白是细胞外基质的组分之一(Okamoto和Fujiwara,2006);
-其引起编码I型胶原(COL1A1)的基因的表达水平增加,I型胶原是细胞外基质的组分之一;
-其引起编码双糖链蛋白聚糖(BGN)的基因的表达水平增加,双糖链蛋白聚糖是细胞外基质的组分之一;
-其引起编码巢蛋白的基因的表达水平增加,巢蛋白是真皮表皮界的组分之一(Aumailley等人,1984);
-其引起编码生腱蛋白C(TNC)的基因的表达水平增加,生腱蛋白C是真皮表皮界的组分之一(Marionnet等人,2006),并且还参与胶原纤维收缩(Tamaoki等人,2005);
-其引起编码多效营养因子(PTN)的基因的表达水平增加,多效营养因子是参与成纤维细胞和角质形成细胞之间的相互作用的蛋白质(Florin等人,2005);
-其引起编码热激蛋白(HSP90A)的基因的表达水平增加,热激蛋白参与调节蛋白酶体的活性,蛋白酶体是使得降解受损蛋白质成为可能的体系(Morishima等人,2005);
-其引起编码serpin1H(HSP47)的基因的表达水平增加,serpin1H是参与调节胶原纤维形成的蛋白质(Kuroda和Tajima,2004);
-其引起编码波形蛋白的基因的表达水平增加,波形蛋白是成纤维细胞细胞骨架的组分之一(Rappersberger等人,1990)。
在如上文定义的用途中使用的N-酰基氨基酸可以是游离酸形式或者部分或全部地是成盐形式。当它是成盐形式时,其特别包括碱金属盐(例如钠、钾或锂盐)、碱土金属盐(例如钙、镁或锶盐)、铵盐或氨基醇的盐(例如(2-羟基乙基)铵盐)。它还可以包括金属盐,例如锌或锰二价盐或者铁、镧、铈或铝三价盐。通常,所述N-酰基氨基酸的成盐程度还取决于其pKA和其将掺入其中的组合物中的盐浓度。
根据本发明的另一种特定变通方式,仅一种上文定义的N-酰基氨基酸被用于含有美容学上可接受的介质的组合物中。
根据本发明的另一种特定变通方式,使用选自上文定义的那些的N-酰基氨基酸的混合物。
根据另一个特定方面,本发明的主题是如上文定义的用途,其中N-酰基氨基酸是N-棕榈酰基丙氨酸。
根据另一个特定方面,本发明的主题是如上文定义的用途,其中N-酰基氨基酸是N-棕榈酰基甘氨酸。
根据另一个特定方面,本发明的主题是如上文定义的用途,其中N-酰基氨基酸是N-棕榈酰基异亮氨酸。
根据另一个特定方面,本发明的主题是如上文定义的用途,其中N- 酰基氨基酸是N-椰油酰基丙氨酸。
术语“N-椰油酰基丙氨酸”意欲指通过使丙氨酸与来源于椰子油的脂肪酸的活化衍生物酰化所获得的N-酰基丙氨酸的混合物。
如上文定义的N-酰基氨基酸通常通过使相应的氨基酸或其盐进行N-酰化而获得。
当涉及N-酰基氨基酸的混合物时,所述混合物例如通过使由所有来源的蛋白质的总水解所产生的氨基酸混合物进行N-酰化而获得。
本发明的主题还有意欲延缓皱纹出现和/或减缓细胞老化的非治疗性处置人体的方法,其特征在于给其应用含有美容学上可接受的介质和有效量的至少一种N-酰基氨基酸的组合物,其中所述N-酰基氨基酸选自N-棕榈酰基丙氨酸、N-棕榈酰基甘氨酸、N-棕榈酰基异亮氨酸和N-椰油酰基丙氨酸。
根据另一个特定方面,本发明的主题是如上文定义的方法,其中N-酰基氨基酸是N-棕榈酰基丙氨酸。
根据另一个特定方面,本发明的主题是如上文定义的方法,其中N-酰基氨基酸是N-棕榈酰基甘氨酸。
根据另一个特定方面,本发明的主题是如上文定义的方法,其中N-酰基氨基酸是N-棕榈酰基异亮氨酸。
根据另一个特定方面,本发明的主题是如上文定义的方法,其中N-酰基氨基酸是N-椰油酰基丙氨酸。
在如上文定义的用途和方法中,N-酰基氨基酸通常用于局部应用于皮肤和粘膜的组合物中。所述的局部应用组合物包含0.01%至10%质量、更特别是0.1%至5%质量、最特别是1%至5%质量的所述N-酰基氨基酸。所述的治疗或处置或所述的用途通过将所述的局部应用组合物应用于欲治疗的皮肤或粘膜表面来实施。
根据另一个方面,本发明的主题是“抗老化”美容用组合物,其特征在于其包含0.01%-10%质量、更特别是0.1%-5%质量、最特别是1%-5%质量的N-酰基氨基酸,所述N-酰基氨基酸选自N-棕榈酰基甘氨酸、N-棕榈酰基丙氨酸、N-棕榈酰基异亮氨酸和N-椰油酰基丙氨酸。
在所述方法或所述用途中使用的组合物通常是稀的水溶液或水-醇溶液的形式;简单乳剂或复乳的形式,例如油包水(W/O)、水包油(O/W)或水包油包水(W/O/W)乳剂,其中油是植物或矿物性质的;或粉末的形式。也可以将它们分散在或浸润于织物材料或无纺材料上,不管这些材料是擦拭布(wipes)、纸巾或覆盖物(clothing)。
如上文定义的N-酰基氨基酸通常与多种类型的用于美容用配制物的佐剂或活性成分组合,不管它们是脂肪物质、有机溶剂、增稠剂、胶凝剂、软化剂、抗氧化剂、遮光剂、稳定剂、发泡剂、芳香剂、离子或非离子型乳化剂、填充剂、多价螯合剂、螯合剂、防腐剂、化学屏蔽剂或无机屏蔽剂、精油、染料、色素、亲水性或亲脂性活性剂、润湿剂(例如甘油)、防腐剂、着色剂、芳香剂、美容用活性剂、无机或有机防晒剂、无机填充剂(例如氧化铁、氧化钛和滑石粉)、合成填充剂(例如尼龙和交联或非交联聚(甲基丙烯酸甲酯))、硅酮高弹体、丝云母或植物提取物或者脂囊泡或通常用于美容品工业的任意其它成分。
作为可与如上文定义的N-酰基氨基酸组合的油的实例,可以提到的有:矿物油,例如液体石蜡、液体矿酯、异构烷烃或白矿物油(white mineral oils));动物来源的油,例如角鲨烯或角鲨烷;植物油,例如甜杏仁油、椰子油、蓖麻油、西蒙得木油、橄榄油、菜子油、花生油、葵花油、小麦胚芽油、玉米胚芽油、大豆油、棉子油、苜蓿油、罂粟油、南瓜籽油、月见草油、小米油、大麦油、黑麦油、红花油、烛果油、西番莲花油、榛子油、棕榈油、牛油树脂、杏仁油、美叶油(beauty-leaf oil)、大蒜芥油(sisymbrium oil)、鳄梨油、金盏花油;乙氧基化植物油;合成油,例如脂肪酸酯,例如肉豆蔻酸丁酯、肉豆蔻酸丙酯、肉豆蔻酸鲸蜡酯、棕榈酸异丙酯、硬脂酸丁酯、硬脂酸十六烷基酯、硬脂酸异丙酯、硬脂酸辛酯、硬脂酸异鲸蜡酯、油酸十二烷基酯、月桂酸己酯或二辛酸丙二醇酯;衍生自羊毛脂酸(lanolic acid)的酯,例如羊毛脂酸异丙酯或羊毛脂酸异鲸蜡酯,脂肪酸甘油单酯、甘油二酯和甘油三酯,例如三庚酸甘油酯、苯甲酸烷基酯、聚-α-烯烃、聚烯烃如聚异丁烯、合成异烷烃如异十六烷或异十二烷、全氟代油和硅油。在所述硅油中,可以更具体提到的有聚二甲基硅氧烷、甲基苯基聚硅氧烷、 胺修饰的硅酮、脂肪酸修饰的硅酮、醇修饰的硅酮、脂肪酸和醇修饰的硅酮、聚醚基团修饰的硅酮、环氧修饰的硅酮、氟基团修饰的硅酮、环状硅酮和烷基修饰的硅酮。
作为可以与该活性剂组合的其它脂肪,可以提及的有脂肪醇或脂肪酸。
在可以合并入包含如上文定义的N-酰基氨基酸的美容用配制物的增稠和/或乳化聚合物中,例如有:丙烯酸或丙烯酸衍生物的均聚物或共聚物、丙烯酰胺均聚物或共聚物、丙烯酰胺衍生物的均聚物或共聚物、丙烯酰氨基甲基丙磺酸/乙烯基单体/丙烯酸三甲基氨基乙基酯氯化物均聚物或共聚物、植物或生物合成来源的水胶体(例如黄原胶、刺梧桐树胶、角叉菜胶(carrageenates)、海藻酸盐);硅酸盐;纤维素及其衍生物;淀粉及其亲水性衍生物;聚氨基甲酸酯。
在可用于产生能够被用于制备含有作为本发明主题的N-酰基氨基酸的W/O乳剂的凝胶化水相的聚电解质型聚合物中,有例如丙烯酸/2-甲基-[(1-氧代-2-丙烯基)氨基]-1-丙磺酸(AMPS)共聚物、丙烯酰胺/2-甲基-[(1-氧代-2-丙烯基)氨基]-1-丙磺酸共聚物、2-甲基-[(1-氧代-2-丙烯基)氨基]-1-丙磺酸/(2-羟基乙基)丙烯酸酯共聚物、2-甲基-[(1-氧代-2-丙烯基)氨基]-1-丙磺酸均聚物、丙烯酸均聚物、丙烯酰基乙基三甲基氯化铵/丙烯酰胺共聚物、AMPS/乙烯吡咯烷酮共聚物、丙烯酸和其基于碳的链包括10至30个碳原子的烷基丙烯酸酯的共聚物以及AMPS和其基于碳的链包括10至30个碳原子的烷基丙烯酸酯的共聚物。申请人分别以如下名称出售这类聚合物:SimulgelTM EG、SepigelTM305、SimulgelTM NS、SimulgelTM800和SimulgelTM A。
在可用于本发明的蜡中,可以提及的例如有:蜂蜡;巴西棕榈蜡;小烛树蜡;小冠巴西棕蜡(ourioury wax);日本蜡(Japan wax);木栓纤维蜡(cork fiber wax)或甘蔗蜡;石蜡;褐煤蜡;微晶蜡;羊毛蜡;地蜡;聚乙烯蜡;氢化油;硅氧烷蜡;植物蜡;在环境温度下为固体的脂肪醇和脂肪酸;在环境温度下为固体的甘油酯。
在可用于本发明的乳化剂中,可以提及的例如有:脂肪酸、乙氧基化脂肪酸、山梨醇脂肪酸酯、乙氧基化脂肪酸酯、聚山梨酯、聚甘油酯、乙 氧基化脂肪醇、蔗糖酯、烷基多苷、脂肪醇硫酸酯和磷酸酯或者烷基多苷与法国专利申请2668080、2734496、2756195、2762317、2784680、784904、2791565、2790977、2807435和2804432中记载的脂肪醇的混合物。
作为可以与如上文定义的N-酰基氨基酸组合的活性成分的实例,可以提及的有:具有使颜色变淡和脱色素作用的化合物,例如熊果苷、曲酸、氢醌、鞣花酸、维生素C、磷酸抗坏血酸酯镁、多酚提取物、葡萄提取物、松树提取物、酒提取物、橄榄提取物、pond提取物、N-酰化蛋白质、N-酰化肽、N-酰化氨基酸、N-酰化蛋白质的部分水解物、氨基酸、肽、总蛋白水解物、部分蛋白水解物、多元醇(例如甘油或丁二醇)、尿素、吡咯烷酮羧酸或该酸的衍生物、甘草次酸、α-没药醇、糖或糖衍生物、多糖或其衍生物、羟酸(例如乳酸)、维生素、维生素衍生物(例如视黄醇)、维生素E及其衍生物、矿物质、酶、辅酶(例如辅酶Q10)、激素或激素样物质、大豆提取物(例如RaffermineTM)、小麦提取物(例如TensineTM或GliadineTM)、植物提取物(例如富含单宁的提取物、富含异黄酮的提取物或富含萜的提取物)、淡水藻或盐水藻提取物、精蜡(essential waxes)、细菌提取物、矿物质、通常的脂质、诸如神经酰胺或磷脂的脂质、具有减肥作用的活性剂(例如咖啡因或其衍生物)、对油性皮肤而言具有抗微生物活性或净化作用的活性剂(例如LipacideTM PVB)、具有供能或刺激性质的活性剂(例如SepitonicTM M3或PhysiogenylTM)、泛醇及其衍生物(例如SepicapTM MP)、抗老化活性剂(例如SepiliftTM DPHP、LipacideTM PVB、SepivinolTM或SepivitalTM)、保湿活性剂(例如SepicalmTM S、SepicalmTM VG和SepiliftTM DPHP)、“抗光老化”抗老化活性剂、保护真皮表皮界完整性的活性剂、增加细胞外基质组分合成的活性剂、具有减肥、紧肤或排水活性的活性剂(例如咖啡因、茶碱、cAMP、绿茶、鼠尾草、银杏、常春藤、马栗、竹、假叶(ruscus)、假叶树、积雪草、欧石南、绣线菊、墨角藻、迷迭香或柳)、在皮肤上产生“热”感的活性剂(例如皮肤毛细血管循环的激活剂(实例:烟酸盐/酯))或者在皮肤上产生“新鲜”感的产物(实例:薄荷醇及衍生物)组成。
作为可掺入本发明的组合物的防晒剂,可以提及的有在化妆品导则 76/768/EEC,(修订版),附件VII中出现的所有那些。
以下实验研究解释说明了本发明,但是不限制本发明。本发明提出:如上文定义的N-酰基氨基酸调节来源于成人真皮的复制衰老性成纤维细胞的遗传特性,因而促进了细胞外基质的产生或保护并同时减少了皮肤炎症,因此能够延缓皱纹。该研究还证明:所述N-酰基氨基酸编码促进成纤维细胞与ECM之间的相互作用以及成纤维细胞与角质形成细胞之间的相互作用的蛋白质。所有这些遗传改变增强了它们的“抗老化”性质。
具体实施方式
本发明的N-酰基氨基酸就复制衰老性人真皮成纤维细胞而言的“恢复”效力的证明:
方案
将来源自成人真皮的并且进行加速老化(16代培养物)或未进行加速老化(8代培养物)的正常人成纤维细胞在存在或不存在以下四种N-酰基氨基酸中的每一种的情况下培养96小时:N-棕榈酰基甘氨酸、N-棕榈酰基丙氨酸、N-棕榈酰基异亮氨酸和N-椰油酰基丙氨酸。在实验结束时,洗涤并提取细胞用于基因组分析。该分析通过Q-PCR(定量聚合酶链反应)进行。
结果
图1和2显示,在老化人成纤维细胞中测试的N-酰基氨基酸引起的基因调节至少编码了促进细胞外基质的产生或限制其降解和/或还有减少皮肤炎症的蛋白质。
图1显示的图说明了所测试的N-酰基氨基酸中的每一种减少与正常人成纤维细胞老化有关的基因过表达的能力。
图2A和2B的图说明了所测试的N-酰基氨基酸中的每一种补偿与正常人成纤维细胞老化有关的基因表达的降低的能力。
对于这些图中的每一幅图,结果以与年轻细胞(100%)相比基因表达的相对水平的改变百分比表示,直方图上方的百分比表示恢复百分比,并且所示的缩略语是按照官方Genbank命名法给出的。
这些图证明了以下结果:
-棕榈酰基丙氨酸引起了编码促炎细胞因子IL-6和金属蛋白酶MMP-1的基因的表达水平降低,并且还引起了编码皮肤桥蛋白(DPT)和I型胶原(COL1A1)的基因的表达水平增加。
-棕榈酰基甘氨酸引起了编码IL-6和MMP-1的基因的表达水平降低,并且还引起了编码DPT、巢蛋白(NID)、生腱蛋白C(TNC)、多效营养因子(PTN)和热激蛋白(HSP90A)的基因的表达水平增加。
-棕榈酰基异亮氨酸引起了编码IL-6和serpin2B的两种基因的表达水平降低,并且还引起了编码DPT、COL1A1、双糖链蛋白聚糖(BGN)、NID、TNC、PTN、HSP90A、serpin1H(HSP47)和波形蛋白的基因的表达水平增加。
-椰油酰基丙氨酸引起了编码IL-6的基因的表达水平降低,并且还引起了编码DPT、NID、TNC、PTN和HSP90A的基因的表达水平增加。
除了它们的抗老化性质、特别是它们保护细胞外基质或促进其产生的能力以外,所测试的所有N-酰基氨基酸都表现出抗炎作用。一方面与其它刺激的活性成分相比,或者另一方面与能够引起基质产生减少的抗炎分子相比,这种双重效力赋予了它们明确的优点。最后,这些LAA能够引起其它基因调节,从而增强它们的抗老化效力。
本发明的N-酰基氨基酸的“抗皱”效力的体内证明
方案
为了对具有皮肤老化皱纹的45-76岁的高加索人个体(约20名志愿者/组)的脸部进行每日两次局部应用,将所测试的N-酰基氨基酸配制成在乳化剂对MontanovTM202和MontanovTM82、增稠剂SepiplusTM400和MontanoxTM60D中的1%乳膏凝胶。
参比的市售脂肽产品也按照相同的实验方案进行测试。
为本研究所选的解剖区域是眼周围区域(鱼尾纹)。
治疗周期为42天。
以前已经通过将测试制剂的贴剂应用48小时证明了没有皮肤刺激性。
结果
结果以与参比市售脂肽产品相比总皱纹表面积和皱纹数表示。
N-棕榈酰基丙氨酸使总皱纹表面积减少15%。
N-棕榈酰基甘氨酸、N-棕榈酰基异亮氨酸和N-椰油酰基丙氨酸分别使皱纹数减少35%、40%和33%。
图3归纳了在测试开始时和在用(A)参比脂肽或(B)N-棕榈酰基甘氨酸每日两次处置达42天后治疗区域(鱼尾纹)的各种照片。
美容用配制物实施例
成分 | % |
水 | 适量 |
甘油 | 5 |
氯苯甘油醚 | 0.3 |
MontanovTM202 | 2 |
MontanovTM82 | 1 |
LanolTM P | 1.5 |
植物角鲨烷 | 7 |
聚异丁烯 | 13 |
KetrolTM T | 0.15 |
N-棕榈酰基甘氨酸 | 1 |
MontanoxTM60DF | 0.5 |
SepiplusTM400 | 0.8 |
SepicideTM LD | 0.7 |
芳香剂 | 0.1 |
三乙醇胺在水中的50%溶液 | 0.15 |
下文给出了用作成分的商品的定义:
KetrolTM T是Kelco公司出售的黄原胶。
LanolTM P是SEPPIC公司出售的具有稳定作用的添加剂。
MontanoxTM60DF:SEPPIC公司出售的用20mol环氧乙烷进行聚乙氧基化的硬脂山梨坦;
MontanovTM82是基于十六十八醇和椰油酰葡糖苷的乳化剂;
MontanovTM202(二十烷基葡糖苷、花生醇+山萮醇)是SEPPIC公司出售的自乳化组合物,例如WO98/17610中记载的那些;
SepicideTMLD:SEPPIC公司出售的防腐剂;
SepiplusTM400:INCI名:聚丙烯酸酯13/聚异丁烯/聚山梨酯20。
说明书中引用的参考文献
Albini等人,1988:Albini等人,Coll.Relat.Res.8(1):23-37(1988);"Decline of fibroblast chemotaxis with age of donor and cell passage number″.
Aumailley等人,1984:Aumailley等人,-J.Biol.Chem.262(24):11532(1984);"The cellular interactions of laminin fragments.Cell adhesion correlates with two fragment-specific high affinity binding sites".
Bradley,Hayflick和Schimke,1976:Bradley,Hayflich和Schimke,J.Biol.Chem.251(12):3521-9(1976);"Protein degradation in human fibroblasts(WI-38).Effects of aging,virall transformations and amino acid analogs″.
Chen等人,2007:Chen等人,Methods Mol Bio1.371:179-89(2007);"Methods of cellular senescence induction using oxidative stress″.
Florin等人,2005:Florin等人,J.Cell Sci.118(Pt9):1981-9.(Epub2005);"Increased keratinocyte proliferation by JUN-dependent expression of PTN and SDF-1in fibroblasts″.
Goldstein,1990:Goldstein,Science,249(4973):1129-33(1990);"Replicative senescence:thc human fibroblast comes of age″.
Jelaska和Korn,1998:Jelaska和Korn,J.CellPhysiol.175(1):19-29(1998);"Anti-Fas induces apoptosis and proliferation in human dermal fibroblasts:differences between foreskin and adult fibroblasts″.
Kawanishi和Oikawa:Kawanishi和Oikawa,Ann N Y Acad.Sci.Jun;1019:278-84(2004);"Mechanism of telomere shortening by oxidative stress″.
Kessler-Becker等人,2004:Kessler-Becker等人,Exp Dermatol.13(11):708-14(2004):″High plasminogen activator inhibitor type2expression is a hallmark of scleroderma fibroblasts in vitro″
Khorramizadeh等人,1999:Khorramizadeh等人,Mol Cell Biochem.194(1-2):99-108(1999);″Aging differentially modulates the expression of collagen and collagenase in dermal fibroblasts″.
Kimah,2003:Kim等人,Toxicol.Lett.15;146(1d:65-73(2003);"The mechanism of retinol-induced irritation and its application to anti-irritant development″.
Kuroda和Tajima,2004:Kuroda和Taiima,JCutan.Pathol.31(3):241-6(2004);"HSP47is a useful marker for skin fibroblasts in formalin-fixcd,paraffin-embedded tissue specimens".
Ma等人,2001:Ma等人,Clin.Exp.Dermatol.Oct;26(7):592-9(2001);″Chronological ageing and photoageing of the fibroblasts andthe dermal connective tissue".
Macieira-Coelho,2000:Macieira-Coelho,Prog Mol Subcell Biol.24:51-80(2000);"Comparative biology of cell immortalization".
Marionnet等人,(2006):Marionnet等人,J Invest Dermatol.126(5):971-9(2006);
″Interactions between fibroblasts and keratinocytes in morphogenesis of dermal epidermal junction in a model of reconstructcd skin".
Miltyk等人,1996:Miltyk等人,Pol.J.Pharmacol.48(6):609-13(1996);″Inhibition of prolidase activity by non-steroid anti-inflammatory drugs in cultured human skin fibroblasts".
Miyoshi等人,2006:Miyoshi等人,Proc.Natl.Acad.Sci.USA.Feb7;103(6):1727-31(2006);"Age-dependent cell death and the role of ATP in hydrogen peroxide-induced apoptosis and necrosis″;
Morishima等人,2005:Morishima等人,Biochemistry.44(49):16333-40(2005);"Regulation of cytochrome P4502E1by heat shock protein 90-dependent stabilization and CHIP-dependent proteasomal degradation".
Okamoto和Fujiwara,2006:Okamoto和Fujiwara,Connect Tissue Res.47(4):177-89(2006);″Dermatopontin,a novel player in the biology of the extracellular matrix″.
Omoigui,2007:Omoigui,Immun Ageing.4:I(2007);"The Interleuhin-6inflammation pathway from cholesterol to aging--role of statins,bisphosphonates and plant polyphenols in aging and age-related diseases".
Papanicolaou等人,2006:Papanicolaou等人,AnnIntern Med.15;128(2):127-37(2006);"The pathophysiologic roles of interleukin-6in human disease".
Ramasamy等人,2005:Ramasamy等人,Glycobiology15(7):16R-28R.(2005);"Advanced glycation end products and RAGE:a common thread in aging,diabetes,neurodegeneration,andinflammation".
Rappersberger等人,1990:Rappersberger等人,J Invest Dermatol.199094(5):700-5(1990);"Immunogold staining of intermediate-sized filaments of the vimentin type in human skin:a postem bedding immunoelectron microscopic study".
Rhim,1991:Rhim,Yonsei Med J.32(3):195-206(1991);Current state-of-the-art in human cell transformation in culture.
Saguet等人,2006:Saguet等人,Eur J Dermatol.16(4):368-74(2006);"Comparison of ultraviolet B-induced imbalance of antioxidant status in foreskin-and abdominal skin-derived human fibroblasts″.
Tamoki等人,2005:Tamoki等人,Am J Pathol.Jul;167(1):71-80(2005);"Tenascin-C regulates recruitment of my ofibroblasts during tissue repair after myocardial injury".
Vaeto等人,2007:Vaeto等人,Mech Ageing Dev.128(1):83-91(2007)(Epub2006Nov21);"Inflammatory networks in ageing,age-related diseases and longevity".
Walston等人,2006:Walston等人,Am J Epidemiol.163(1)18-26(2006)(Epub2005Nov23);"Serum antioxidants,inflammation,and total mortality in older women".
Claims (3)
1.意欲延缓皱纹出现和/或减缓细胞老化的非治疗性处置人体的方法,其特征在于给其应用含有美容学上可接受的介质和有效量的至少一种N-酰基氨基酸的组合物,其中所述N-酰基氨基酸选自N-棕榈酰基甘氨酸和N-棕榈酰基异亮氨酸。
2.如权利要求1所定义的方法,其中N-酰基氨基酸是N-棕榈酰基丙氨酸。
3.如权利要求1所定义的方法,其中N-酰基氨基酸是N-棕榈酰基异亮氨酸。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0855792A FR2935378B1 (fr) | 2008-08-29 | 2008-08-29 | Utiisation de n-acyl aminoacides comme principes actifs cosmetiques et pharmaceutiques, capables de reduire l'etat inflammatoire des fibroblastes replicatifs senescents issus du derme humain adulte; compositions cosmetiques anti-age |
FR0855792 | 2008-08-29 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801335033A Division CN102137839A (zh) | 2008-08-29 | 2009-07-24 | 选自n-棕榈酰基丙氨酸、n-棕榈酰基甘氨酸和n-棕榈酰基异亮氨酸的n-酰基氨基酸作为人皮肤真皮的衰老复制性成纤维细胞的遗传特性的调节活性剂的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103432011A true CN103432011A (zh) | 2013-12-11 |
Family
ID=40456224
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801335033A Pending CN102137839A (zh) | 2008-08-29 | 2009-07-24 | 选自n-棕榈酰基丙氨酸、n-棕榈酰基甘氨酸和n-棕榈酰基异亮氨酸的n-酰基氨基酸作为人皮肤真皮的衰老复制性成纤维细胞的遗传特性的调节活性剂的用途 |
CN2013103468131A Pending CN103432011A (zh) | 2008-08-29 | 2009-07-24 | N-酰基氨基酸作为人皮肤真皮的衰老复制性成纤维细胞的遗传特性的调节活性剂的用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801335033A Pending CN102137839A (zh) | 2008-08-29 | 2009-07-24 | 选自n-棕榈酰基丙氨酸、n-棕榈酰基甘氨酸和n-棕榈酰基异亮氨酸的n-酰基氨基酸作为人皮肤真皮的衰老复制性成纤维细胞的遗传特性的调节活性剂的用途 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2331496B1 (zh) |
KR (1) | KR20110056281A (zh) |
CN (2) | CN102137839A (zh) |
FR (1) | FR2935378B1 (zh) |
WO (1) | WO2010023390A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2948563A1 (fr) * | 2009-07-28 | 2011-02-04 | Seppic Sa | Utilisation de n-acyl aminoacides comme principes actifs cosmetiques et pharmaceutiques, capables de restaurer les forces isometriques des fibroblastes du derme humain adulte |
FR2959936B1 (fr) * | 2010-05-14 | 2012-08-03 | Physica Pharma | Composition nasales a visee systemique a base de cocoyl proline ou d 'au moins un de ses constituants |
FR2965479B1 (fr) * | 2010-09-30 | 2012-09-28 | Seppic Sa | Nouvelles emulsions cosmetiques eau-dans-huile comprenant des derives n-acyle de haut point de fusion et procedes pour leurs preparations |
FR2971941B1 (fr) | 2011-02-24 | 2013-08-02 | Physica Pharma | Compositions pharmaceutiques administrables par voie cutanee et destinees au traitement local de la dermatite atopique canine |
FR2971943B1 (fr) | 2011-02-24 | 2013-08-02 | Physica Pharma | Compositions pharmaceutiques a action locale administrables par application cutanee |
TW201538155A (zh) | 2014-03-10 | 2015-10-16 | Benjamin M Yu | 活性成份輔助組成物及將活性成份化合物遞送給對象之方法 |
KR101896211B1 (ko) * | 2018-02-20 | 2018-09-06 | 정연호 | 마스크 팩 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1436614A (en) * | 1972-07-17 | 1976-05-19 | Thomae Gmbh Dr K | Dermatological compositions |
US4016287A (en) * | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
CN1336817A (zh) * | 1999-01-08 | 2002-02-20 | 瑞·J·余 | 含n-乙酰基-醛糖胺或n-乙酰基氨基酸的局部用组合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK255889D0 (da) * | 1989-05-25 | 1989-05-25 | Novo Nordisk As | Fremgangsmaade til fremstilling af organiske forbindelser |
JP3202777B2 (ja) * | 1992-01-24 | 2001-08-27 | リンテック株式会社 | 経皮吸収促進剤及びテープ製剤 |
US7374783B2 (en) * | 2004-07-27 | 2008-05-20 | Miyoshi Kasei, Inc. | Powders coated with specific lipoamino acid composition and cosmetics containing the same |
US8758838B2 (en) * | 2005-08-31 | 2014-06-24 | Johnson & Johnson Consumer Companies, Inc. | Anti-inflammatory compositions and methods of use |
-
2008
- 2008-08-29 FR FR0855792A patent/FR2935378B1/fr not_active Expired - Fee Related
-
2009
- 2009-07-24 CN CN2009801335033A patent/CN102137839A/zh active Pending
- 2009-07-24 EP EP09740375.2A patent/EP2331496B1/fr active Active
- 2009-07-24 KR KR1020117004432A patent/KR20110056281A/ko not_active Application Discontinuation
- 2009-07-24 WO PCT/FR2009/051489 patent/WO2010023390A1/fr active Application Filing
- 2009-07-24 CN CN2013103468131A patent/CN103432011A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1436614A (en) * | 1972-07-17 | 1976-05-19 | Thomae Gmbh Dr K | Dermatological compositions |
US4016287A (en) * | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
CN1336817A (zh) * | 1999-01-08 | 2002-02-20 | 瑞·J·余 | 含n-乙酰基-醛糖胺或n-乙酰基氨基酸的局部用组合物 |
Non-Patent Citations (2)
Title |
---|
CARL R THORNFELDT: ""Chronic inflammation is etiology of extrinsic aging"", 《JOURNAL OF COSMETIC DERMATOLOGY》 * |
SUMNER H. BURSTEIN ET AL: ""Potential anti-inflammatory actions of the elmiric (lipoamino) acids"", 《BIOORGANIC & MEDICINAL CHEMISTRY》 * |
Also Published As
Publication number | Publication date |
---|---|
EP2331496A1 (fr) | 2011-06-15 |
FR2935378B1 (fr) | 2015-03-27 |
FR2935378A1 (fr) | 2010-03-05 |
KR20110056281A (ko) | 2011-05-26 |
WO2010023390A1 (fr) | 2010-03-04 |
EP2331496B1 (fr) | 2016-06-01 |
CN102137839A (zh) | 2011-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11752168B2 (en) | Methods of using cosmetic compositions comprising exopolysaccharides derived from microbial mats | |
KR101884411B1 (ko) | 미백 및 보습용 기능성 화장료 조성물 | |
CN103432011A (zh) | N-酰基氨基酸作为人皮肤真皮的衰老复制性成纤维细胞的遗传特性的调节活性剂的用途 | |
EP2355782A2 (en) | A complex of active vegetal stem cells and a cosmetic composition | |
WO2009127058A1 (en) | Skin care compositions and methods of use thereof | |
KR20080030023A (ko) | 주름 방지·개선제 | |
CN110384645A (zh) | 一种抗皱皮肤调理剂、美颈霜及制备方法 | |
CN106265977B (zh) | 牡丹籽提取物及制备方法和应用、包括其的皮肤外用剂 | |
JP6850732B2 (ja) | 紅藻アクロカエティウム・モニリフォルメ(Acrochaetium moniliforme)の細胞を培養するための方法、そのバイオマスの抽出物を得るための方法および化粧料におけるその使用 | |
CN110393689A (zh) | 一种具有抗衰功效的精华组合物及其制备方法 | |
CN113712874A (zh) | 一种含水溶性硅素的护肤品及其制备方法和应用 | |
US20180140537A1 (en) | Active complex for a cosmetic product against skin ageing | |
CN102137652B (zh) | 选自n-棕榈酰基丙氨酸、n-棕榈酰基甘氨酸、n-棕榈酰基异亮氨酸和n-椰油酰基丙氨酸的n-酰基氨基酸作为调控表达存活蛋白的核形式的人皮肤表皮的基底角质形成细胞的比例的活性剂的用途以及含有其的抗老化美容用组合物 | |
KR20050103903A (ko) | 노화되거나 환경에 손상된 피부를 치료하기 위한 국소적조성물 및 치료 방법 | |
CN114588061A (zh) | 一种抗衰除皱组合物及其制备方法和护肤品 | |
CN113368003A (zh) | 一种具有熬夜肌修护功效的组合物及其制备方法和应用 | |
CN112969920A (zh) | 评估物质或组合物预防、减缓或消除皮肤或嘴唇老化迹象的能力的方法 | |
CN114632045B (zh) | 一种抗衰老组合物及制备方法与应用 | |
KR100472919B1 (ko) | 수용성 미백 조성물 및 그를 함유하는 피부 미백용 화장료조성물 | |
CN113662876A (zh) | 多肽美颜精华液以及制备方法 | |
CH706016A2 (de) | Auf Stammzellen der Epidermis und Dermis und auf deren Mikro-Umgebung wirkende kosmetische Zusammensetzung. | |
AU2009238172B2 (en) | Cosmetic compositions comprising exopolysaccharides derived from microbial mats, and use thereof | |
KR102397975B1 (ko) | 키레놀을 포함하는 피부 보습용 피부외용제 조성물 | |
CN115590782A (zh) | 一种补水紧致皮肤的组合物及其制备方法 | |
JP2023054706A (ja) | 肌美容用化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131211 |